301 related articles for article (PubMed ID: 11776321)
1. The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Cho JH; Yun CH; Seo HS; Koga T; Dan T; Koo BA; Kim HY
Thromb Haemost; 2001 Dec; 86(6):1512-20. PubMed ID: 11776321
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin.
Cho J; Seo H; Yun C; Koo B; Yoshida S; Koga T; Dan T; Kim H
Thromb Res; 2000 Oct; 100(1):97-107. PubMed ID: 11053622
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Peternel L; Stegnar M; Drevensek G; Budihna MV; Bozic M; Zega A; Stalc A; Cerne M; Urleb U
Thromb Haemost; 2005 Mar; 93(3):437-42. PubMed ID: 15735792
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Schumacher WA; Heran CL; Steinbacher TE
J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
[TBL] [Abstract][Full Text] [Related]
9. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
10. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury.
Malm K; Dahlbäck B; Arnljots B
Plast Reconstr Surg; 2003 Apr; 111(5):1659-66. PubMed ID: 12655212
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
17. Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.
Hennan JK; Hong TT; Shergill AK; Driscoll EM; Cardin AD; Lucchesi BR
J Pharmacol Exp Ther; 2002 Jun; 301(3):1151-6. PubMed ID: 12023550
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
[TBL] [Abstract][Full Text] [Related]
20. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
